S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Strongbridge Biopharma Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00%)
(As of 10/5/2021)
Today's Range
50-Day Range
52-Week Range
684,684 shs
Average Volume
866,464 shs
Market Capitalization
$135.66 million
P/E Ratio
Dividend Yield

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Strongbridge Biopharma logo

About Strongbridge Biopharma

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.


Tudor Capital Europe LLP : Form 8.3 - Strongbridge Biopharma Plc
June 29, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$30.73 million
Book Value
$0.98 per share


Net Income
$-45.08 million
Net Margins
Pretax Margin




Free Float
Market Cap
$135.66 million

Company Calendar

Last Earnings


Overall MarketRank

1.63 out of 5 stars

Medical Sector

1002nd out of 1,391 stocks

Pharmaceutical Preparations Industry

477th out of 669 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

Is Strongbridge Biopharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Strongbridge Biopharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SBBP, but not buy additional shares or sell existing shares.
View analyst ratings for Strongbridge Biopharma
or view top-rated stocks.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analysts' expectations of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%.
View Strongbridge Biopharma's earnings history

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $36 M-, compared to the consensus revenue estimate of $36.28 million.

What price target have analysts set for SBBP?

3 Wall Street analysts have issued 1-year price targets for Strongbridge Biopharma's shares. Their forecasts range from $3.25 to $10.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $6.63 in the next twelve months. This suggests a possible upside of 231.3% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • John H. Johnson, Chief Executive Officer & Director
  • Richard S. Kollender, President & Chief Financial Officer
  • Fredric Cohen, Chief Medical Officer
  • Brian Conner, Chief Compliance Officer
  • Peter J. Valentinsson, Senior Vice President-Global Technical Operations

What other stocks do shareholders of Strongbridge Biopharma own?

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Caxton Corp (11.83%), Stonepine Capital Management LLC (6.62%), Rubric Capital Management LP (4.53%), Man Group plc (2.90%), Morgan Stanley (2.62%) and Renaissance Technologies LLC (2.02%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma

Which major investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Morgan Stanley, Two Sigma Advisers LP, Caxton Corp, Renaissance Technologies LLC, Millennium Management LLC, Weiss Asset Management LP, and OMERS ADMINISTRATION Corp.
View insider buying and selling activity for Strongbridge Biopharma
or view top insider-selling stocks.

Which major investors are buying Strongbridge Biopharma stock?

SBBP stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Man Group plc, Rubric Capital Management LP, Jane Street Group LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma
or or view top insider-buying stocks.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.00.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45.08 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 72 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Where are Strongbridge Biopharma's headquarters?

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at (610) 254-9200 or via email at [email protected].

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.